Alpha-Lipoic Acid Shows Stroke Potential
Ischemic Microenvironment-Targeted Bioinspired Lipoprotein Sequentially Penetrates Cerebral Ischemic Lesions to Rescue Ischemic Stroke.
We examined how alpha-lipoic acid (ALA) impacts stroke recovery, particularly through a newly developed delivery system designed to target ischemic brain lesions. This system uses bioinspired lipoproteins to carry ALA, allowing it to reach the areas most affected by stroke more effectively than standard methods.
In experiments with mice experiencing a transient middle cerebral artery occlusion (a model for stroke), we observed that the ALA-loaded lipoprotein system accumulated significantly in the ischemic brain tissue—2.29 times more than a nontargeted version. This increased delivery resulted in several positive outcomes, such as restoring neurological function, reducing brain cell death, and lessening inflammation, which is key for healing after a stroke.
Overall, our findings suggest that ALA, when delivered effectively to the right brain areas, has considerable potential to improve recovery from ischemic strokes. This innovative approach opens new avenues for treating strokes and enhancing patient outcomes.
Read More
Investigating AA-9 for stroke
Discovery of neuroprotective Agents: Potent, brain Penetrating, lipoic acid derivatives for the potential treatment of ischemic stroke by regulating oxidative stress and inflammation - a Preliminary study.
In our exploration of neuroprotective agents for treating ischemic stroke, we focused on lipoic acid, a naturally occurring compound that shows promise in this area. However, we noticed that standard lipoic acid has limitations, including low efficacy and instability, which hinder its direct use in treatments.
To address these issues, we synthesized 37 lipoic acid derivatives, with compound AA-9 emerging as the standout performer. Through in vitro experiments using tert-butyl hydroperoxide to mimic oxidative damage, we found that AA-9 demonstrated excellent therapeutic potential and an impressive safety profile.
Our subsequent studies using a rat model of ischemic stroke revealed that AA-9 significantly reduces the impact of stroke. This beneficial effect seems to stem from its antioxidant and anti-inflammatory properties, specifically by activating key cellular pathways that help protect the brain. Additionally, AA-9 outperformed regular alpha-lipoic acid in terms of stability and bioavailability, making it an exciting candidate for further research.
Overall, we believe AA-9 holds great promise as a neuroprotective agent for ischemic stroke and warrants further investigation to unlock its full potential.
Read More
Alpha-lipoic acid reduces stroke risk in diabetic patients
Morbidity and mortality of patients with diabetic neuropathy treated with pathogenetically oriented alpha-lipoic acid versus symptomatic pharmacotherapies - A nationwide database analysis from Hungary.
Researchers analyzed a decade of Hungarian healthcare records comparing two treatment approaches for diabetic neuropathy: alpha-lipoic acid (ALA), which targets underlying disease mechanisms, versus symptomatic medications that only manage pain and symptoms.
Among matched patient groups, those receiving ALA experienced significantly fewer strokes—a 29% lower risk compared to the symptomatic treatment group. The benefits extended beyond stroke, with ALA-treated patients also showing reduced rates of heart attacks, heart failure, cancer events, and overall mortality.
However, ALA showed no protective effect against lower limb amputation. While these findings are compelling, researchers emphasize this is an observational study and note the results require confirmation through rigorous clinical trials before drawing firm conclusions about ALA's superiority.
Read More
ALA's potential in stroke treatment
A comprehensive review on alpha-lipoic acid delivery by nanoparticles.
We investigated the potential of alpha-lipoic acid (ALA) in treating cerebral ischemia, a condition often associated with strokes. The idea behind using ALA is its antioxidant properties, which might help mitigate damage caused during a stroke.
One of the notable findings from the review is the promising application of ALA encapsulated within niosomes for this purpose. Niosomes can enhance the delivery of ALA to the brain, potentially improving cell protection during ischemic events.
However, it's essential to note that while there are indications of ALA's benefits, the study did not conclusively determine its effectiveness in treating stroke independently. This makes it crucial for us to exercise caution when interpreting the results and considering ALA as a therapeutic option for stroke treatment.
Read More
ALA moderately improved vascular markers post-stroke
The effect of alpha-lipoic acid supplementation on vascular function and inflammation in patients newly experienced stroke.
We conducted a randomized, double-blind, placebo-controlled trial with 80 stroke patients to test whether alpha-lipoic acid (ALA) could improve vascular function and reduce inflammation. Half received 600 mg of ALA daily for 12 weeks, while the other half received placebo. Using ultrasound and blood tests, we measured changes in blood vessel thickness, vessel flexibility, and inflammatory markers.
ALA supplementation significantly improved blood vessel flexibility and reduced a key inflammation marker. However, two other inflammatory proteins showed no meaningful change. Overall, the findings suggest that ALA may help protect against future heart and blood vessel problems in stroke survivors, though additional research is needed.
Read More